Jazz Pharmaceuticals (NASDAQ:JAZZ) Given Buy Rating at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by Needham & Company LLC in a research note issued to investors on Thursday, Benzinga reports. They presently have a $222.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 101.25% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on JAZZ. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Stifel Nicolaus upped their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, March 22nd. Piper Sandler upped their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Finally, Truist Financial reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $195.25.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $110.31 on Thursday. Jazz Pharmaceuticals has a twelve month low of $106.61 and a twelve month high of $146.70. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 1.53 and a beta of 0.63. The firm has a 50-day moving average of $117.26 and a two-hundred day moving average of $121.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. As a group, analysts expect that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction on Friday, March 1st. The shares were bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of JAZZ. Rise Advisors LLC lifted its position in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the period. Cape Investment Advisory Inc. lifted its position in Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after purchasing an additional 292 shares during the period. Covestor Ltd lifted its holdings in shares of Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after acquiring an additional 345 shares during the period. Assetmark Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 119 shares during the period. Finally, Spire Wealth Management lifted its holdings in shares of Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 238 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.